| 1. Peer Reviewed Title: Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. Author: Hamoda H; Ashok PW; Flett GM; Templeton A Source: Contraception. 2005;71:327-332. Abstract: The aim of the study was to assess the use, efficacy and factors influencing the outcome of medical abortion at 9–13 weeks’ gestation. Retrospective chart review of consecutive women undergoing medical abortion at 9–13 weeks’ gestation was done. A total of 1927 abortions were carried out at 9–13 weeks’ gestation, of which 1076 (55.8%) were undertaken medically. Efficacy decreased with increasing gestation (p=.02). Surgical evacuation was carried out in 45 (4.2%) women including 10 (2.7%) at 64–70 days, 11 (3.3%) at 71–77 days, 10 (5.1%) at 78–84 days and 14 (8.0%) at 85–91 days of gestation (p=.02). Indications for surgery included continuing pregnancy [16 (1.5%) women], retained sac [5 (0.5%)], incomplete abortion [20 (1.9%)] and emergency curettage for bleeding [4 (0.4%)]. The number of misoprostol doses used and the induction-to-abortion interval both significantly increased with gestation (p < .001), while analgesia requirements did not vary with increasing gestation (p=.18). Medical abortion at 9–13 weeks’ gestation is an effective alternative to surgery. Medical methods should be offered routinely at these gestations, thus increasing women’s choice. (author's) Language: English Keywords: UNITED KINGDOM | RESEARCH REPORT | RETROSPECTIVE STUDIES | PREGNANT WOMEN | PREGNANCY, FIRST TRIMESTER | ABORTION | RU-486 | MISOPROSTOL | GESTATIONAL AGE | BLEEDING | UTERINE ASPIRATOR | Developed Countries | Europe, Western | Europe | Studies | Research Methodology | Population Characteristics | Demographic Factors | Population | Pregnancy | Reproduction | Fertility Control, Postconception | Family Planning | Hormone Antagonists | Hormones | Endocrine System | Physiology | Biology | Prostaglandins, Synthetic | Prostaglandins | Fetus | Signs and Symptoms | Diseases | Surgical Equipment | Equipment and Supplies Document Number: 284460 Notification |
 |
||
 |
Information & Knowledge for Optimal Health (INFO) Project 111 Market Place Suite 310, Baltimore, MD 21202 Phone: 410-659-6300 Fax: 410-659-6266 Security & Privacy Policy |  |